Literature DB >> 7868846

How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo.

G D Tollefson1, S L Holman.   

Abstract

The onset of action of antidepressant medications is commonly believed to require three or more weeks based on clinical observation and corollary receptor-based hypotheses. However, this is not congruent with early published observations with the tricyclic antidepressants and has been recently challenged. Time to response has implications for treatment compliance, dose adjustment, patient well-being, and the associated economic costs of depression. Weekly improvement on the 21-item Hamilton Depression Rating Scale (HAMD21) from baseline and time to response for fluoxetine- and placebo-treated patients were compared. Data from six double-blind clinical trials of 6-7 weeks' duration, in which 1447 patients with DSM-III-R major depression had been randomly allocated to fluoxetine (n = 962) or placebo (n = 485), were pooled. Analysis of variance was used to evaluate HAMD21 improvement and the Kaplan-Meier estimate was used to evaluate time to response (> or = 50% improvement in HAMD21). Improvement in HAMD21 was statistically significantly greater for fluoxetine than placebo beginning at Week 1 and continuing throughout all weeks of therapy. However, Week 1 and 2 results varied among the individual studies. HAMD factors of cognition and psychomotor status revealed the most rapid changes for fluoxetine-treated compared with placebo-treated patients. The probability of achieving a clinical response, defined as a HAMD21 score reduction from baseline of at least 50%, was similar for both fluoxetine (0.043) and placebo (0.049) at the end of Week 1. However, by Week 2 and thereafter the probability of a response was greater for fluoxetine than placebo.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7868846     DOI: 10.1097/00004850-199400940-00003

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  15 in total

1.  Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI.

Authors:  Stella Bitran; Amy H Farabaugh; Victoria E Ameral; Rachel A LaRocca; Alisabet J Clain; Maurizio Fava; David Mischoulon
Journal:  Int Clin Psychopharmacol       Date:  2011-07       Impact factor: 1.659

Review 2.  Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.

Authors:  Ewgeni Jakubovski; Anjali L Varigonda; Nicholas Freemantle; Matthew J Taylor; Michael H Bloch
Journal:  Am J Psychiatry       Date:  2015-11-10       Impact factor: 18.112

Review 3.  Prospects for the development of new treatments with a rapid onset of action in affective disorders.

Authors:  J C Soares; S Gershon
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 4.  A risk-benefit assessment of pharmacotherapies for clinical depression in children and adolescents.

Authors:  J Renaud; D Axelson; B Birmaher
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

5.  Long-term Ameliorative Effects of the Antidepressant Fluoxetine Exposure on Cognitive Deficits in 3 × TgAD Mice.

Authors:  Li Jin; Li-Feng Gao; Dong-Sheng Sun; Hao Wu; Qun Wang; Dan Ke; Hao Lei; Jian-Zhi Wang; Gong-Ping Liu
Journal:  Mol Neurobiol       Date:  2016-06-21       Impact factor: 5.590

6.  Early improvement as a predictor of eventual antidepressant treatment response in severely depressed inpatients.

Authors:  Marlijn Vermeiden; Astrid M Kamperman; Monique E Vulink; Walter W van den Broek; Tom K Birkenhäger
Journal:  Psychopharmacology (Berl)       Date:  2014-10-23       Impact factor: 4.530

7.  Future directions for serotonin and antidepressants.

Authors:  Francesc Artigas
Journal:  ACS Chem Neurosci       Date:  2013-01-16       Impact factor: 4.418

Review 8.  A reproductive subtype of depression: conceptualizing models and moving toward etiology.

Authors:  Jennifer L Payne; Jennifer Teitelbaum Palmer; Hadine Joffe
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

Review 9.  Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; David A Luckenbaugh; Husseini K Manji; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2008-06       Impact factor: 4.384

Review 10.  Time course of response to antidepressants in late-life major depression: therapeutic implications.

Authors:  Ellen M Whyte; Mary Amanda Dew; Ariel Gildengers; Eric J Lenze; Ashok Bharucha; Benoit H Mulsant; Charles F Reynolds
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.